The intra-individual heterogeneity of response to BRAF-inhibitor (i.e., dabrafenib) was further investigated by Carlino et al. in 23 patients with BRAF-mutated MM, imaged through 18F-FDG PET/CT at baseline and after 15 days of targeted therapy [38]. Here, BRAF is linked to Miyoshi myopathy.